Related Experiment Video
Updated: May 13, 2026
10:17
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Drugs after 1992; an equation with many remaining unknowns.
1Amsterdam, The Netherlands.
The International Journal of Risk & Safety in Medicine
|March 21, 2013
Summary
The European Community's common market for pharmaceuticals, driven by economic interests, prompted professional reactions in the Netherlands. This conference explored the implications for health and medical care within a member state.
Area of Science:
- Medical Policy
- European Union Health Law
- Pharmaceutical Economics
Background:
- The Nederlands Tijdschrift Door Geneeskunde periodically sponsors expert meetings on current medical topics.
- A conference was held on June 15th, 1990, to discuss the impending European Community common market for pharmaceuticals.
- The development was motivated by international economic interests, raising questions about its impact on health and medical care.
Purpose of the Study:
- To report on professional reactions within a European Community member state to the common market for pharmaceuticals.
- To analyze the motivations behind the pharmaceutical market integration.
- To assess the potential consequences for national health and medical care systems.
Main Methods:
- Expert meeting sponsored by a national medical journal.
- Discussion and reporting of professional viewpoints.
- Analysis of policy-driven changes in the pharmaceutical sector.
Main Results:
- The conference highlighted professional reactions to a market development driven by economic rather than health considerations.
- Views expressed represented the perspective of one member state regarding the European Community's pharmaceutical market integration.
- The report reflects concerns about the balance between economic interests and healthcare priorities.
Conclusions:
- The establishment of a common market for pharmaceuticals by the European Community presents challenges and requires careful consideration of health and medical care implications.
- National professional bodies need to articulate their perspectives on supranational health policy developments.
- The integration of pharmaceutical markets necessitates a critical evaluation of its impact on patient well-being and healthcare delivery.
Related Concept Videos
01:21Drug Accumulation During Multiple Dosing: Repetitive IV Injections
Calculating drug dosage and accumulation in multiple-dose regimens is crucial for achieving therapeutic efficacy while avoiding toxicity. This involves determining the plasma drug concentrations over time to optimize dosing schedules. The principle of superposition is fundamental in this process, allowing for the prediction of drug concentration in plasma following multiple doses based on single-dose data.The principle of superposition asserts that the plasma concentration-time curves from...
01:01Dosage Regimens: Partial Pharmacokinetic Parameters
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
01:24Pharmacokinetic–Pharmacodynamic Relationship: Problems
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
01:25Drug Distribution as One-Compartment Model and Elimination by Nonlinear Pharmacokinetics: Overview
Drug administration can occur through various routes, each of which may result in a different process of elimination. This process is often mixed with nonlinear and linear processes. It's important to understand that a single drug can be metabolized into different metabolites through parallel processes.
For instance, consider the metabolism of sodium salicylate. This compound is metabolized into two distinct substances: a glucuronide and a glycine conjugate. The rate of conjugation depends on...
For instance, consider the metabolism of sodium salicylate. This compound is metabolized into two distinct substances: a glucuronide and a glycine conjugate. The rate of conjugation depends on...
01:13Parameters Affecting Nonlinear Elimination: Zero-Order Input, First-Order Absorption and Two-Compartment Model
Drugs administered through various routes can lead to nonlinear elimination, resulting in complex pharmacokinetic behaviors crucial to understanding efficacious drug dosing.
When a drug is administered through a constant intravenous infusion and eliminated via nonlinear pharmacokinetics, it follows zero-order input. For example, oral drugs undergo first-order absorption upon administration and are eliminated through nonlinear pharmacokinetics.
In the case of subcutaneously administered drugs,...
When a drug is administered through a constant intravenous infusion and eliminated via nonlinear pharmacokinetics, it follows zero-order input. For example, oral drugs undergo first-order absorption upon administration and are eliminated through nonlinear pharmacokinetics.
In the case of subcutaneously administered drugs,...
01:28Pharmacokinetic–Pharmacodynamic Relationship: Dose to Pharmacological Effect
A drug’s dosage and pharmacokinetic properties determine how quickly it acts, how intense its effects are, and how long it lasts. Higher doses increase drug concentration at receptor sites, producing a hyperbolic curve when pharmacologic response is plotted against drug dose. Converting this scale to a log-linear format results in a sigmoidal curve, better representing dose–response relationships.For drugs following a one-compartment model, the pharmacologic response is directly proportional to...